C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
← catalyst calendarNCT07037277 · readout ≤ 134 d
Sponsored by Atea Pharmaceuticals, Inc. (industry) · AVIR — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
880estimated
Sites
107
Countries
Egypt, France, Germany +14
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-02 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- HEPATITIS C VIRUS CHRONIC INFECTION
- Hepatitis C, Chronic
- Hepatitis C Virus Infection
- Hepatitis C
Interventions
- Drug: Bemnifosbuvir-Ruzasvir — also filed as (BEM/RZR)
- Drug: Sofosbuvir-Velpatasvir — also filed as (SOF/VEL)
Primary outcome
what the primary-completion date above is the date OFPortion of subjects achieving HCV RNA less than the lower limit of quantitation (LLOQ) at week 24
measured Day 1 through Week 24
Permalink · AVIR's whole pipeline · Catalyst calendar · Every registered study · What changed